Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
<h4>Background</h4>Chronic pruritus is a global clinical problem with a high impact on the quality of life and lack of specific therapies. It is an excruciating and frequent symptom of e.g. uncurable renal, liver and skin diseases which often does not respond to conventional treatment wi...
Main Authors: | Sonja Ständer, Dorothee Siepmann, Ilka Herrgott, Cord Sunderkötter, Thomas A Luger |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-06-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20532044/?tool=EBI |
Similar Items
-
Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose
by: Miguel Muñoz, et al.
Published: (2019-03-01) -
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
by: Miguel Muñoz, et al.
Published: (2020-09-01) -
Does neurokinin-1-receptor antagonist aprepitant diminish the efficacy of cyclophosphamide-based chemotherapy?
by: Carlos Eduardo Paiva, et al. -
The Neuromodulatory Effect of Antipruritic Treatment of Chronic Prurigo
by: Claudia Zeidler, et al.
Published: (2019-09-01) -
Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting
by: Chae Seong Lim, et al.
Published: (2013-03-01)